FDA extends review of Orexigen's NB32 By: MarketMinute.com Stock News June 11, 2014 at 12:52 PM EDT The Food and Drug Administration extended its review of Orexigen Therapeutics Inc.'s (Nasdaq: OREX) weight loss medication NB32. The stock price tumbled $1.16 to $5.64.